#AsukaPharmaceuticalHoldings

For the third quarter of the fiscal year ending March 2026, net sales amounted to ¥54,486 million (9.1% Year-over-Year increase), operating income was ¥4,911 million (10.6% Year-over-Year decrease), and net income attributable to owners of the parent was ¥3,904 million (4.7% Year-over-Year decrease).

Net sales of 54.4 billion yen, a 9.1% increase year-over-year. Operating income was 4.9 billion yen, a 10.6% decrease year-over-year. Full-year earnings guidance forecasts net sales of 71.0 billion yen and operating income of 6.0 billion yen.